-
Why metal prices are soaring to record highs
-
Stocks tepid in thin pre-Christmas trade
-
UN experts slam US blockade on Venezuela
-
Bethlehem celebrates first festive Christmas since Gaza war
-
Set-piece weakness costing Liverpool dear, says Slot
-
Two police killed in explosion in Moscow
-
EU 'strongly condemns' US sanctions against five Europeans
-
Arsenal's Kepa Arrizabalaga eager for more League Cup heroics against Che;sea
-
Thailand-Cambodia border talks proceed after venue row
-
Kosovo, Serbia 'need to normalise' relations: Kosovo PM to AFP
-
Newcastle boss Howe takes no comfort from recent Man Utd record
-
Frank warns squad to be 'grown-up' as Spurs players get Christmas Day off
-
Rome pushes Meta to allow other AIs on WhatsApp
-
Black box recovered from Libyan general's crashed plane
-
Festive lights, security tight for Christmas in Damascus
-
Zelensky reveals US-Ukraine plan to end Russian war, key questions remain
-
El Salvador defends mega-prison key to Trump deportations
-
Stranger Things set for final bow: five things to know
-
Grief, trauma weigh on survivors of catastrophic Hong Kong fire
-
Asian markets mixed after US growth data fuels Wall St record
-
Stokes says England player welfare his main priority
-
Australia's Lyon determined to bounce back after surgery
-
Stokes says England players' welfare his main priority
-
North Korean POWs in Ukraine seeking 'new life' in South
-
Japanese golf star 'Jumbo' Ozaki dies aged 78
-
Johnson, Castle shine as Spurs rout Thunder
-
Thai border clashes hit tourism at Cambodia's Angkor temples
-
From predator to plate: Japan bear crisis sparks culinary craze
-
Asian markets mostly up after US growth fuels Wall St record
-
'Happy milestone': Pakistan's historic brewery cheers export licence
-
Chevron: the only foreign oil company left in Venezuela
-
US denies visas to EU ex-commissioner, four others over tech rules
-
Dynamite Blockchain Delivers Record Q3 2025
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
SMX's Integrated Value Proposition: One System, Many Markets, Compounding Leverage
-
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
-
Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026
-
Pantheon Resources PLC Announces TR-1: Notification of Major Holdings
-
Bridgeline Expands Footprint with Closeout Retailer Choosing HawkSearch for Its On-Site Search Experience and Personalization
-
Koepka leaves LIV Golf: official
-
US slams China policies on chips but will delay tariffs to 2027
-
Arsenal reach League Cup semis with shoot-out win over Palace
-
Contenders Senegal, Nigeria start Cup of Nations campaigns with wins
-
Tunisia ease past Uganda to win Cup of Nations opener
-
S&P 500 surges to record after strong US economic report
-
UK police say no action against Bob Vylan duo over Israel army chant
-
Libya's top military chief killed in plane crash in Turkey
-
Venezuela passes law to jail backers of US oil blockade
-
French parliament passes emergency budget extension
US cancels $590 million contract with Moderna for bird flu shot
US President Donald Trump's administration on Wednesday canceled a $590 million contract with Moderna to develop an avian flu vaccine, the US biotech company said.
It marked the latest move against vaccines by Health Secretary Robert F. Kennedy Jr, who has spent decades promoting misinformation about immunization.
The contract, announced on January 17 -- three days before Trump took office -- was for an mRNA vaccine targeting the H5N1 influenza strain, which has been circulating in birds and cattle.
Experts have warned the virus could jump to humans and spark a pandemic.
American pharmaceutical and biotechnology company Moderna disclosed the news as it announced positive results from an early stage clinical trial of 300 people designed to test safety and immune response.
"While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program," said CEO Stephane Bancel in a statement.
"These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats."
The statement added Moderna would "explore alternatives" for funding the development and manufacturing of the vaccine.
Dr. Ashish Jha, a public health expert who served as former president Joe Biden's Covid-19 response coordinator, reacted with dismay.
"The attack on mRNA vaccines is beyond absurd," he posted on X. "It was President Trump's Operation Warp Speed that gave us mRNA vaccines."
D.Sawyer--AMWN